Index Performance
Overview
Description
Developed by Lux Capital, the Lux Bio + Tech Index™ is a secular investment theme that covers companies innovating to further the molecular understanding of the "omics stack" to companies building "operating systems" for the future of drug discovery and ultimately even drug development. Over time these companies have transformed from radical, even heretical, ideas to undeniable technical, scientific, and clinical proof points. The last decade has ushered in an unparalleled understanding of the molecular basis of biology, enabled by emergent tool kits to engineer and perturb biology, ultimately increasing the velocity of discovery. Today, Moore's Law-like cost curves exist along many axes in biotech and have given rise to an era of precise, high fidelity, large scale, highly reproducible, and increasingly automated biological and chemical experimentation and discovery. The modern scientist-entrepreneur not only sits at the wetbench but also has proficiency to deconvolute high dimensional and historically unmanageable data with GPUs, the cloud, and the array of advances from machine learning and deep learning.
Full methodology- TickerLUXBT
- Inception Date04/23/2021
- WeightingCustom
- # of holdings54
What's inside?
Holdings
All holdings as of December 8, 2023
BridgeBio Pharma, Inc. (BBIO) | 9.50% | $5.657B | 1,110.36% | 52.65% | 582.88x |
Third Harmonic Bio, Inc. (THRD) | 4.73% | $401.608M | N/A | N/A | N/A |
Nuvalent, Inc. (NUVL) | 4.63% | $4.041B | N/A | N/A | N/A |
Schrödinger, Inc. (SDGR) | 3.90% | $2.009B | 15.11% | 55.53% | 8.32x |
10X Genomics, Inc. (TXG) | 3.21% | $5.087B | 17.22% | 56.08% | 7.78x |
Recursion Pharmaceuticals, Inc. (RXRX) | 2.93% | $1.583B | -19.96% | -35.55% | 27.48x |
Tango Therapeutics, Inc. (TNGX) | 2.70% | $936.265M | 55.09% | 94.29% | 20.57x |
CRISPR Therapeutics AG (CRSP) | 2.68% | $5.127B | -100.00% | N/A | 12.39x |
Evotec SE (EVO) | 2.64% | $3.492B | 21.97% | 19.27% | 4.39x |
Ionis Pharmaceuticals, Inc. (IONS) | 2.45% | $6.986B | -9.74% | 94.60% | 10.14x |
Editas Medicine, Inc. (EDIT) | 2.42% | $858.391M | 12,604.76% | 71.63% | 13.08x |
Certara, Inc. (CERT) | 2.30% | $2.626B | 1.03% | 44.61% | 6.64x |
Alector, Inc. (ALEC) | 2.23% | $514.915M | -38.67% | 75.22% | -0.05x |
Dyne Therapeutics, Inc. (DYN) | 2.11% | $686.179M | N/A | N/A | N/A |
Exscientia Plc (EXAI) | 2.11% | $686.137M | 51.81% | -25.17% | 4.59x |
Verve Therapeutics, Inc. (VERV) | 2.10% | $1.005B | 235.52% | -2.63% | 56.36x |
Sana Biotechnology, Inc. (SANA) | 2.10% | $733.336M | N/A | N/A | N/A |
Regeneron Pharmaceuticals, Inc. (REGN) | 2.10% | $90.003B | 14.53% | 83.89% | 6.57x |
Caribou Biosciences, Inc. (CRBU) | 2.09% | $513.785M | 616.38% | 91.10% | 2.58x |
Nurix Therapeutics, Inc. (NRIX) | 1.89% | $417.132M | 71.13% | 81.68% | 3.08x |
Janux Therapeutics, Inc. (JANX) | 1.84% | $415.978M | 38.83% | 80.14% | 16.05x |
Nkarta, Inc. (NKTX) | 1.78% | $133.967M | N/A | N/A | N/A |
Nuvation Bio, Inc. (NUVB) | 1.77% | $291.196M | N/A | N/A | N/A |
Olink Holding AB (OLK) | 1.76% | $3.189B | 40.54% | 69.96% | 10.88x |
ATAI Life Sciences NV (ATAI) | 1.76% | $200.873M | 262.50% | 14.94% | 32.58x |
Roivant Sciences Ltd. (ROIV) | 1.62% | $7.903B | 196.03% | 78.03% | 81.99x |
Intellia Therapeutics, Inc. (NTLA) | 1.59% | $2.599B | -9.60% | 80.90% | 39.92x |
Denali Therapeutics, Inc. (DNLI) | 1.59% | $2.539B | -64.40% | -74.98% | 5.24x |
Compass Pathways Plc (CMPS) | 1.42% | $400.395M | N/A | N/A | N/A |
Ginkgo Bioworks Holdings, Inc. (DNA) | 1.36% | $2.202B | -16.52% | 42.02% | 9.15x |
Arvinas, Inc. (ARVN) | 1.28% | $1.880B | 14.19% | 95.09% | 0.39x |
Kymera Therapeutics, Inc. (KYMR) | 1.26% | $1.276B | -50.50% | 80.96% | 11.42x |
Revolution Medicines, Inc. (RVMD) | 1.25% | $4.028B | -100.00% | N/A | 86.87x |
SomaLogic, Inc. (SLGC) | 1.17% | $460.377M | -47.14% | 47.23% | -0.03x |
Lyell Immunopharma, Inc. (LYEL) | 1.09% | $483.588M | 733.33% | -20,316.00% | -2.91x |
Beam Therapeutics, Inc. (BEAM) | 1.07% | $2.152B | 8.82% | 56.52% | 12.99x |
Century Therapeutics, Inc. (IPSC) | 1.05% | $142.407M | -93.35% | -1,107.43% | -1.22x |
Ultragenyx Pharmaceutical, Inc. (RARE) | 1.02% | $3.322B | 8.10% | 88.79% | 7.47x |
Relay Therapeutics, Inc. (RLAY) | 1.00% | $1.155B | 7,226.16% | 94.59% | 10.54x |
4D Molecular Therapeutics, Inc. (FDMT) | 0.99% | $638.739M | 3,940.80% | 93.09% | 10.62x |
SAGE Therapeutics, Inc. (SAGE) | 0.96% | $1.200B | 56.18% | 66.68% | 32.07x |
Fate Therapeutics, Inc. (FATE) | 0.94% | $220.868M | -87.02% | -143.83% | -0.34x |
AbCellera Biologics, Inc. (ABCL) | 0.93% | $1.413B | -93.49% | -12.27% | 11.94x |
Stoke Therapeutics, Inc. (STOK) | 0.93% | $212.999M | 13.87% | 63.72% | -4.00x |
ProKidney Corp. (DNAC) | 0.93% | $120.846M | N/A | N/A | N/A |
Vir Biotechnology, Inc. (VIR) | 0.91% | $1.294B | -99.30% | -144.07% | -2.73x |
BioNTech SE (BNTX) | 0.89% | $25.135B | -72.05% | 81.93% | 1.74x |
Alnylam Pharmaceuticals, Inc. (ALNY) | 0.88% | $21.339B | 183.96% | 88.77% | 13.64x |
Adaptive Biotechnologies Corp. (ADPT) | 0.81% | $681.880M | -20.72% | 33.78% | 3.61x |
Prime Medicine, Inc. (PRME) | 0.78% | $827.257M | N/A | N/A | N/A |
Moderna, Inc. (MRNA) | 0.77% | $30.625B | -44.75% | -35.99% | 3.66x |
Erasca, Inc. (ERAS) | 0.74% | $282.533M | N/A | N/A | N/A |
Seer, Inc. (California) (SEER) | 0.69% | $102.224M | 5.23% | 15.81% | -10.02x |
Seres Therapeutics, Inc. (MCRB) | 0.35% | $140.890M | -91.00% | -1,153.87% | 2.73x |